Xospata
| Chemical Name | gilteritinib |
| Dosage Form | Tablet (oral; 40 mg) |
| Drug Class | Kinase inhibitors |
| System | Blood |
| Company | Astellas Pharma |
| Approval Year | 2018 |
Indication
- Indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test